Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 168

Similar articles for PubMed (Select 23084523)

1.

Targeting the androgen receptor.

Friedlander TW, Ryan CJ.

Urol Clin North Am. 2012 Nov;39(4):453-64. doi: 10.1016/j.ucl.2012.07.003. Review.

PMID:
23084523
2.

The evolving paradigm of second-line hormonal therapy options for castration-resistant prostate cancer.

Courtney KD, Taplin ME.

Curr Opin Oncol. 2012 May;24(3):272-7. doi: 10.1097/CCO.0b013e328351059d. Review.

PMID:
22327837
3.

The androgen receptor, androgen synthesis, and new designer antiandrogens for metastatic castration-resistant prostate cancer: teaching old dogs new tricks.

Lieberman R.

Am J Ther. 2013 Mar-Apr;20(2):128-31. doi: 10.1097/MJT.0b013e3182857f8e. No abstract available.

PMID:
23466618
4.

Changing paradigms in management of metastatic Castration Resistant Prostate Cancer (mCRPC).

Gupta E, Guthrie T, Tan W.

BMC Urol. 2014 Jul 25;14:55. doi: 10.1186/1471-2490-14-55. Review.

5.

Androgen receptor directed therapies in castration-resistant metastatic prostate cancer.

Kim W, Ryan CJ.

Curr Treat Options Oncol. 2012 Jun;13(2):189-200. doi: 10.1007/s11864-012-0188-2. Review.

PMID:
22539224
6.

[Prostate cancer and new hormonal treatments: mechanism of action and main clinical results].

Neuzillet Y, Flamand V, Lebdai S, Villers A, Lebret T.

Prog Urol. 2013 Oct;23 Suppl 1:S34-43. doi: 10.1016/S1166-7087(13)70044-7. Review. French.

PMID:
24314737
7.

Development of androgen receptor antagonists with promising activity in castration-resistant prostate cancer.

Shen HC, Balk SP.

Cancer Cell. 2009 Jun 2;15(6):461-3. doi: 10.1016/j.ccr.2009.05.005.

8.

Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model.

Handratta VD, Vasaitis TS, Njar VC, Gediya LK, Kataria R, Chopra P, Newman D Jr, Farquhar R, Guo Z, Qiu Y, Brodie AM.

J Med Chem. 2005 Apr 21;48(8):2972-84.

PMID:
15828836
9.

Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer.

Rehman Y, Rosenberg JE.

Drug Des Devel Ther. 2012;6:13-8. doi: 10.2147/DDDT.S15850. Epub 2012 Jan 16. Review.

10.

Enzalutamide as a second generation antiandrogen for treatment of advanced prostate cancer.

Semenas J, Dizeyi N, Persson JL.

Drug Des Devel Ther. 2013 Aug 27;7:875-81. doi: 10.2147/DDDT.S45703. eCollection 2013. Review.

11.

A novel antiandrogen, Compound 30, suppresses castration-resistant and MDV3100-resistant prostate cancer growth in vitro and in vivo.

Kuruma H, Matsumoto H, Shiota M, Bishop J, Lamoureux F, Thomas C, Briere D, Los G, Gleave M, Fanjul A, Zoubeidi A.

Mol Cancer Ther. 2013 May;12(5):567-76. doi: 10.1158/1535-7163.MCT-12-0798. Epub 2013 Mar 14.

12.

Targeting the androgen receptor pathway in prostate cancer.

Chen Y, Sawyers CL, Scher HI.

Curr Opin Pharmacol. 2008 Aug;8(4):440-8. doi: 10.1016/j.coph.2008.07.005. Epub 2008 Aug 12. Review.

13.

Resistance emerges to second-generation antiandrogens in prostate cancer.

Nelson WG, Yegnasubramanian S.

Cancer Discov. 2013 Sep;3(9):971-4. doi: 10.1158/2159-8290.CD-13-0405.

14.

Beyond castration and chemotherapy: novel approaches to targeting androgen-driven pathways.

Pal SK, Twardowski P, Josephson DY.

Maturitas. 2009 Oct 20;64(2):61-6. doi: 10.1016/j.maturitas.2009.08.004. Epub 2009 Sep 5. Review.

PMID:
19733987
15.

Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer.

Stein MN, Patel N, Bershadskiy A, Sokoloff A, Singer EA.

Asian J Androl. 2014 May-Jun;16(3):387-400. doi: 10.4103/1008-682X.129133. Review.

16.

Targeting the adrenal gland in castration-resistant prostate cancer: a case for orteronel, a selective CYP-17 17,20-lyase inhibitor.

Zhu H, Garcia JA.

Curr Oncol Rep. 2013 Apr;15(2):105-12. doi: 10.1007/s11912-013-0300-1. Review.

PMID:
23371447
17.

Novel concepts in androgen receptor blockade.

Hsieh AC, Ryan CJ.

Cancer J. 2008 Jan-Feb;14(1):11-4. doi: 10.1097/PPO.0b013e318161d13e. Review.

PMID:
18303477
18.

ARN-509: a novel antiandrogen for prostate cancer treatment.

Clegg NJ, Wongvipat J, Joseph JD, Tran C, Ouk S, Dilhas A, Chen Y, Grillot K, Bischoff ED, Cai L, Aparicio A, Dorow S, Arora V, Shao G, Qian J, Zhao H, Yang G, Cao C, Sensintaffar J, Wasielewska T, Herbert MR, Bonnefous C, Darimont B, Scher HI, Smith-Jones P, Klang M, Smith ND, De Stanchina E, Wu N, Ouerfelli O, Rix PJ, Heyman RA, Jung ME, Sawyers CL, Hager JH.

Cancer Res. 2012 Mar 15;72(6):1494-503. doi: 10.1158/0008-5472.CAN-11-3948. Epub 2012 Jan 20.

19.

Landmarks in hormonal therapy for prostate cancer.

Hammerer P, Madersbacher S.

BJU Int. 2012 Oct;110 Suppl 1:23-9. doi: 10.1111/j.1464-410X.2012.11431.x. Review.

PMID:
23046037
20.

[Androgen-deprivation therapy in prostate cancer: clinical evidence and future perspectives].

Pinto F, Calarco A, Totaro A, Sacco E, Volpe A, Racioppi M, D'Addessi A, Bassi PF.

Urologia. 2010 Apr-May;77(2):71-83. Review. Italian.

PMID:
20890863
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk